Kirkland Advises IntraBio on Sale to Shionogi
Kirkland & Ellis advised IntraBio Inc. on an agreement to be acquired by Shionogi & Co., Ltd. IntraBio is a biopharmaceutical company developing and commercializing therapies for neurodegenerative diseases. Under the terms of the agreement, Shionogi Inc. will acquire all outstanding shares of IntraBio for an upfront consideration of $2 billion payable to IntraBio shareholders. Pursuant to the agreement, which was signed by the parties today, IntraBio would become a wholly owned subsidiary of Shionogi Inc., a New Jersey-based subsidiary of Shionogi. The proposed transaction, which is subject to customary closing conditions, would add AQNEURSA (levacetylleucine) and IntraBio’s capabilities in the rare disease area to Shionogi’s growing portfolio.
Read the transaction press release
The Kirkland team included corporate lawyers Graham Robinson, Dan Li, Adam Hustad and Dami Ashaye; tax lawyers Liam Murphy and Olivia Chilcott; executive compensation lawyers Timothy Nelson and Hannah Fraley; employment & labor lawyers Josh Owings and Erin Davey; employee benefits lawyer Justin Coddington; antitrust & competition lawyers, Maria Raptis, Brittany Baker, Daniel Rosenthal, Mackenzie Pike and Jack Borrow; technology & IP transactions lawyer Shellie Freedman; healthcare lawyers Dennis Williams, Kiyong Song, Cooper Barghols; and capital markets lawyers Jennifer Lee and Tamar Donikyan.
